A-Hydrocort

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of A-Hydrocort

Quick Facts

Property Description
Active Ingredient Hydrocortisone (as the sodium succinate salt)
Form Lyophilized powder for injection
Pharmacological Class Glucocorticoid (Corticosteroid)
Origin Synthetic (chemically identical to natural Cortisol)
Route Parenteral (Systemic injection)

What Type of Medicine is A-Hydrocort and What is its Origin?

A-Hydrocort is classified as a potent, synthetic adrenocortical steroid belonging to the Glucocorticoid class of medicines, recognized clinically for its powerful anti-inflammatory action. Its active compound, Hydrocortisone, is a manufactured substance chemically identical to Cortisol, the primary natural hormone of the adrenal glands, which is a key differentiating factor. The drug is strictly a prescription-only product.

Composition and Form: The Rapid Action of Hydrocortisone Sodium Succinate

The unique active compound in this preparation is Hydrocortisone sodium succinate, a specialized, highly soluble salt formulation of Hydrocortisone. A-Hydrocort is supplied as a lyophilized powder for injection, which is reconstituted into a sterile injectable solution. This formulation is distinct because it enables parenteral delivery, which is essential for ensuring rapid systemic absorption. Highly soluble salts like sodium succinate are utilized to achieve the fast therapeutic concentrations often required in acute care.

What is the General Purpose of A-Hydrocort?

The general purpose of A-Hydrocort is to provide powerful, immediate control over severe systemic inflammation or immune hyperactivity through its dominant anti-inflammatory action and broad immunosuppressive effect. Typical use scenarios involve conditions requiring swift stabilization of the body's physiological responses. Furthermore, its composition as Hydrocortisone makes it fundamentally utilized for endocrine replacement to rapidly restore metabolic and systemic functions in cases of severe adrenal hormone deficiency.

What side effects are possible with A-Hydrocort?

Possible side effects and safety information

The official safety profile for A-Hydrocort (Hydrocortisone sodium succinate injection), a systemic glucocorticoid, is structured by regulatory authorities based on the body systems affected and the frequency of occurrence.

Adverse reactions are formally grouped into System-Organ Classes (SOCs). These include effects on the Endocrine System (such as HPA axis suppression and Cushingoid features), Metabolism and Nutrition (including fluid retention and impaired carbohydrate tolerance), Musculoskeletal System (e.g., muscle weakness and osteoporosis), and the Gastrointestinal System (risk of peptic ulceration) [Official Regulatory Labeling].

Adverse effects are categorized by frequency. Effects such as fluid retention, hyperglycemia, and mood changes are frequently classified as common or very common. Less frequent, or rare, events documented in regulatory documents include avascular necrosis and serious anaphylactic reactions [Official Regulatory Labeling].

Time-Related Safety Patterns are also noted: effects such as osteoporosis and the development of cataracts are officially associated with prolonged exposure. Conversely, the label notes that secondary adrenocortical insufficiency may persist for months following treatment cessation [Official Regulatory Labeling].

Safety constraints and contraindications formally defined in prescribing information include systemic fungal infections. Specific notes for the pediatric population address the potential for growth retardation with long-term use [Official Regulatory Labeling].

Overdose and Emergency Response

Overdose and when to seek help

Overdose Profile

A-Hydrocort (hydrocortisone sodium succinate) is generally not expected to cause life-threatening symptoms from an acute, single overdosage. The medication’s acute toxicity is considered to be low. Therefore, treatment for an acute overdose is primarily supportive and symptomatic.

However, repeated administration of very high doses, particularly when continued beyond 48 to 72 hours, may lead to metabolic and hormonal imbalances.

Risk Factors for Chronic Overexposure

  • Long-term high-dose use can result in a condition known as a Cushingoid state (Cushing's syndrome), characterized by a round or puffy face, thinning skin, and increased body fat around the midsection and upper back.
  • Extended high-dose therapy can also be associated with hypernatremia (abnormally high sodium levels in the blood).

When to Seek Medical Attention

If you believe you have received an excess dose of this medication, contact a poison control center or emergency medical services immediately. The most urgent risks related to the drug are usually associated with serious side effects, not necessarily a one-time overdose. Always seek emergency medical help if you experience signs of a severe allergic reaction or other serious adverse events, such as difficulty breathing, swelling of the face, or a seizure.

Therapeutic Uses of A-Hydrocort

The therapeutic applications of A-Hydrocort (Hydrocortisone Sodium Succinate injection) are relevant for easing symptoms associated with acute or disruptive episodes. Its use is indicated for conditions characterized by periods of heightened symptoms, including severe allergic reactions, arthritis, and certain conditions requiring steroid replacement.

Symptom Management and Therapeutic Support

A-Hydrocort is used in clinical settings that involve acute or unstable symptom patterns, such as an adrenal crisis, severe rheumatoid arthritis flares, status asthmaticus, and acute exacerbations of conditions like Systemic Lupus Erythematosus (SLE) or inflammatory bowel disease. This medication helps address symptom clusters that may become intense or disruptive, applied across domains where additional symptomatic support is needed. It is particularly relevant in scenarios where symptoms create noticeable physiological strain, providing support that helps ease the overall symptom load.


Quick Fact: Relief for Systemic Symptom Management

Symptom Type Application Context Patient Benefit
Severe Swelling / Pain Acute flares of autoimmune/rheumatic diseases Supports improved comfort during symptomatic periods
Airway Constriction Critical allergic reactions or asthma crises Supports general well-being during symptomatic phases
Circulatory Instability Acute deficiency of natural cortisol (Adrenal Crisis) Contributes to easing the overall symptom load during collapse

Regulatory References

  1. Hydrocortisone Injection: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use A-Hydrocort? (Hydrocortisone Sodium Succinate Injection)

Official regulatory documents define specific populations who are restricted from or require conditional use of A-Hydrocort (hydrocortisone sodium succinate injection).

Absolute Exclusions (Contraindications)

Use of this medication is strictly forbidden in the following populations and conditions:

  • Systemic Fungal Infections: Patients with an active, widespread fungal infection.
  • Hypersensitivity: Individuals with a known allergy or hypersensitivity to the drug or its components.
  • Premature Infants: Formulations containing the excipient benzyl alcohol are contraindicated in premature infants due to the associated risk of a fatal condition.

Populations Requiring Conditional or Restricted Use

Administration requires careful consideration and patient monitoring if the following conditions are present:

  • Existing Comorbidities: Use is subject to caution in patients with conditions such as ocular herpes simplex (risk of corneal perforation), active or latent peptic ulcer, hypertension, congestive heart failure, or osteoporosis.
  • Infectious Risk: Patients with latent tuberculosis or non-immune status to varicella (chickenpox) or measles require special precautions.
  • Route-Specific Restriction: Intramuscular (IM) administration is specifically contraindicated in adults for the indication of Idiopathic Thrombocytopenic Purpura (ITP).

Age and Data Limitations

  • Infants le 1 Month Old: Safety and effectiveness have not been established in this age group, meaning there is insufficient regulatory data to define eligibility.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation for hydrocortisone outlines several clinically significant interaction patterns with other medicines, specific substances, and physiological conditions, primarily involving metabolic clearance and pharmacodynamic effects.

Metabolic Clearance Alteration (Pharmacokinetic)

Hydrocortisone is a substrate of the Cytochrome P450 3A4 (CYP3A4) enzyme pathway. Co-administration with CYP3A4 inducers, such as the antibacterials Rifampicin or the anticonvulsants Phenytoin and Phenobarbital, is documented to accelerate hydrocortisone metabolism, resulting in reduced plasma exposure. Conversely, co-administration with CYP3A4 inhibitors—including antifungal agents like Ketoconazole and certain HIV protease inhibitors like Ritonavir—can impede hydrocortisone metabolism, leading to increased systemic plasma exposure.

Pharmacodynamic Consequence Reinforcement

  • Concurrent use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) is associated with an increased risk of gastrointestinal ulceration and bleeding.
  • Co-administration with Potassium-Depleting Agents, such as thiazide diuretics, may enhance potassium loss.
  • The effect of hydrocortisone on Oral Anticoagulants is officially reported as variable, with documentation of both reduced and potentiated anticoagulant efficacy.
  • The co-administration of live or live-attenuated vaccines is an interaction-related restriction due to the risk of severe reaction or failure of the expected immune response.

Non-Medicinal and Population-Specific Notes

The regulatory label for hydrocortisone notes that Grapefruit Juice may increase the drug's plasma concentration. Additionally, the metabolic clearance of hydrocortisone is officially recognized as decreased in hypothyroidism and increased in hyperthyroidism, a population-specific factor that alters the resulting systemic exposure.

Mechanism of Action

A-Hydrocort (hydrocortisone) acts as an agonist for the cytosolic Glucocorticoid Receptor (GR), a specific type of intracellular receptor found across most tissues. Upon binding, the activated drug-receptor complex translocates into the cell nucleus to modulate gene expression. This process involves transactivation (promoting anti-inflammatory protein synthesis, like Annexin A1) and transrepression (inhibiting pro-inflammatory transcription factors like NF-kappaB).

This genomic action initiates an anti-inflammatory cascade by indirectly inhibiting the enzyme Phospholipase A2, thereby limiting the production of eicosanoids (prostaglandins and leukotrienes). The mechanism broadly dampens the systemic immune response and leads to a broad systemic physiological reduction in inflammation. Concurrently, the molecule engages mechanisms that regulate metabolic homeostasis, promoting gluconeogenesis and increasing protein catabolism. This action results in elevated systemic blood glucose, which represents a key physiological consequence of the drug's glucocorticoid action.

Dosage and Administration Information

How to Use A-Hydrocort

Administration of A-Hydrocort (hydrocortisone sodium succinate) is strictly limited to parenteral routes due to its formulation as a highly soluble, rapid-acting injectable powder. The routes for systemic use are Intravenous (IV) Injection, Intravenous (IV) Infusion, or Intramuscular (IM) Injection. The method chosen often depends on the urgency of the clinical scenario.


Dosing and Preparation Protocol

The initial adult dose typically ranges from 100 mg to 500 mg of hydrocortisone equivalent, determined by the severity of the patient’s condition. This dose may be repeated at intervals of 2, 4, or 6 hours as necessary. Administration requires precise steps because the medication is supplied as a lyophilized powder.

  • Reconstitution: The powder must first be reconstituted with the appropriate diluent, such as Bacteriostatic Water for Injection.
  • IV Rate: The initial IV injection is performed over a specified time, ranging from 30 seconds for 100 mg to 10 minutes for larger doses (500 mg or more).

Course Duration and Transition

A-Hydrocort is a short-term stabilizer. High-dose intravenous therapy is generally intended to be continued only until the patient is stable, which typically does not exceed 48 to 72 hours. Following this acute period, a transition is made to either a longer-acting injectable or an oral corticosteroid preparation, with the dosage reduced gradually.

Population-Specific Considerations

For pediatric use, dosing is primarily based on the severity of the illness rather than body weight. The daily dose administered to infants and children should not be less than 25 mg.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Mechanism of Action

Research has explored A-Hydrocort's mechanism of action, which involves inhibiting a specific protein. The research explored the drug's impact on the processes associated with inflammation, consistent with its classification as a glucocorticoid.

Studies in Condition A (e.g., Septic Shock)

Multiple clinical trials and meta-analyses have evaluated the use of hydrocortisone (the active component) for conditions requiring rapid corticosteroid support, such as septic shock. The trials typically compare hydrocortisone, often at low doses, to placebo or standard care.

Results from the trials indicated that the drug was associated with a reduction in disease activity in certain critically ill patient groups. Observation periods during the initial treatment phase reported changes in participant status, including a potential for quicker resolution of shock symptoms and a reduced need for vasopressor support.

Studies in Combination Therapy

Research has examined hydrocortisone's impact when co-administered with other agents, such as fludrocortisone or Vitamin C/Thiamine. One study examined whether co-administration with other treatments impacted the patient's time alive and free of vasopressor support, in comparison to hydrocortisone alone. Findings varied across these different combination studies.

Conclusion of Evidence

Research has been conducted to explore the drug's use for acute and chronic inflammatory and autoimmune conditions. Findings were mixed across different patient sub-groups, particularly regarding long-term effects. The body of evidence continues to be refined, and further research is warranted to clarify optimal patient selection and treatment protocols.

Frequently Asked Questions (FAQ)

Common questions about A-Hydrocort (FAQ)


Q: Can A-Hydrocort cause stomach upset?

Regulatory documents list several gastrointestinal adverse reactions associated with the drug. These include common symptoms like nausea, vomiting, and indigestion. More serious reactions, such as peptic ulceration, are documented in the official safety profile.


Q: Does A-Hydrocort interact with blood pressure medications?

Yes, according to the official product information, A-Hydrocort can cause the body to retain sodium and fluid, which may increase blood pressure. This effect may interfere with medications taken to control high blood pressure. Caution is advised for patients with pre-existing hypertension.


Q: How is A-Hydrocort different from other corticosteroids?

Regulatory documents provide data on how the drug compares to other corticosteroids in terms of anti-inflammatory activity. This information indicates that A-Hydrocort is pharmacologically related to other medicines in the same class. For instance, 20 mg of the active ingredient, hydrocortisone, is considered equivalent in activity to 5 mg of prednisone.


Q: Is A-Hydrocort used to treat allergies?

Yes, official indications for A-Hydrocort include the control of severe or highly incapacitating allergic conditions. This includes treatment for severe allergic reactions and acute drug hypersensitivity reactions in patients whose conditions are intractable to conventional therapies.


Q: Is A-Hydrocort considered a strong medicine?

Official information classifies the drug as a potent anti-inflammatory agent. The classification reflects its use in managing severe medical conditions. It is used in situations requiring rapid and immediate management, such as acute, life-threatening adrenocortical insufficiency.


Q: What are the official, regulated uses of A-Hydrocort?

According to the official product label, A-Hydrocort is regulated for a broad range of uses. These include treating adrenocortical insufficiency and conditions like shock, as well as managing certain rheumatic, allergic, gastrointestinal, and respiratory disorders.


Q: Does taking A-Hydrocort affect sleep patterns?

Yes, official safety information lists potential effects on the nervous system. Insomnia, which is defined as trouble sleeping, is a specific adverse reaction reported with the use of this medication.


Q: Are there common changes in appetite associated with A-Hydrocort?

Yes, according to the regulatory documents, changes in appetite are a commonly reported side effect. Specifically, an increased appetite is listed as an adverse effect associated with this drug.


Q: Can A-Hydrocort cause weight gain?

Weight gain is listed as an adverse reaction in the official product information. This effect is associated with the drug's impact on metabolism, which includes sodium and fluid retention.


Q: Is hair loss or thinning listed as a side effect of A-Hydrocort?

Official documents list various potential effects on the skin and hair. These include the possibility of thinning of the scalp hair, as well as hirsutism (unusual hair growth).


Q: Is there an expected range of time for A-Hydrocort effects to last?

Following the injection, demonstrable pharmacological effects are generally seen within one hour. Regulatory documents indicate that the excretion of the administered dose from the body is nearly complete within approximately 12 hours.


Q: Does the timing of A-Hydrocort use relative to food matter?

A-Hydrocort is administered as an injection (parenteral route), so the timing of its use in relation to food does not affect how it is absorbed. However, if a patient is later transitioned to the oral form of hydrocortisone, official guidance often notes that the oral form is generally taken with food to help prevent stomach irritation.


Q: Can A-Hydrocort be taken with common pain relievers like Tylenol?

Official drug interaction listings do not identify a known major interaction between hydrocortisone and acetaminophen ( Tylenol). However, it is important to discuss any combined use with a healthcare provider.


Q: Are there known issues taking A-Hydrocort with supplements like Vitamin D?

Regulatory safety guidance acknowledges that long-term use of this class of medication can lead to bone loss, or osteoporosis. Regulatory guidance notes that maintaining adequate intake of Vitamin D and calcium may be advisable to support bone health.


Q: Is it possible for herbal remedies to interact with A-Hydrocort?

Official guidance states that there is often not enough information to confirm the safety of combining this drug with various herbal remedies. Consultation with a healthcare professional is recommended.


Q: What information is available about A-Hydrocort use in people over 65?

Regulatory documentation has not demonstrated age-specific problems in the elderly that would limit the drug's usefulness. However, caution is advised because older patients are more likely to have age-related conditions, such as decreased liver, heart, or kidney function, which may warrant careful consideration.


Q: Is A-Hydrocort use during pregnancy described in official documentation?

Official documentation addresses use during pregnancy. It is classified as Pregnancy Category C by the US FDA, which indicates the drug is generally reserved for use only when the potential benefits clearly outweigh the potential risks to the developing fetus.


Q: Is A-Hydrocort appropriate for individuals with kidney conditions?

Regulatory information advises caution regarding use in patients with renal insufficiency or kidney conditions. This is because the effects of the corticosteroid may be enhanced or prolonged in the presence of kidney dysfunction.


Q: Is there official information on A-Hydrocort use while breastfeeding?

Official information confirms that hydrocortisone is present in breast milk. While the amount is generally considered unlikely to be harmful to the infant, women receiving high systemic doses may experience a temporary reduction in lactation.


Q: What should a user know about missed A-Hydrocort use?

Missing a dose can be a serious situation, especially for a potent injectable medicine. Regulatory guidance emphasizes that users should contact their doctor or pharmacist immediately for instructions on what to do next. It is prohibited to take a double dose to make up for the missed one.


Q: Can A-Hydrocort affect the results of medical lab tests?

Yes, A-Hydrocort may affect the results of certain medical lab tests. Since the drug is chemically identical to the body’s natural cortisol, it can interfere with tests designed to measure your natural cortisol levels. It may also cause changes in blood mineral levels and white blood cell counts.


Q: Why do people often confuse A-Hydrocort with prednisone?

The primary reason for comparison is that the two drugs belong to the same corticosteroid class and are prescribed for similar conditions. Regulatory information confirms their pharmacological relationship by providing the anti-inflammatory equivalence between hydrocortisone and prednisone.

How should A-Hydrocort be stored and disposed of?

Official Storage and Disposal Instructions

A-Hydrocort (hydrocortisone sodium succinate sterile powder) has strict storage requirements for both the powder and the prepared solution to maintain stability.

Product Form Temperature / Protection Stability Period
Unreconstituted Powder Store at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F). Up to Expiration Date
Reconstituted Solution Store at Controlled Room Temperature and protect from light. Use within 12 hours
Reconstituted Solution Refrigerated conditions. Use within 24 hours

All medicinal waste, including any portion of the prepared solution not used within the stability period, must be discarded and disposed of in accordance with local requirements. The medication must always be kept out of the sight and reach of children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of A-Hydrocort found in:

A-Z Index: